BioTech
Amgen scores late-stage trial success for eczema and myasthenia gravis treatments, but faces stiff competition
Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded in late-stage trials, but the therapies
Jonathan Wosen and Allison DeAngelis
September 24, 2024